Morphosys
The MorphoSys AG (proper spelling: MorphoSys AG) is a German biotechnology company. The exchange-traded and listed on the Nasdaq company is headquartered in Martinsried near Munich. MorphoSys is one of self-reported the world's leading biotechnology companies focusing on fully human antibodies. On the basis of its technologies MorphoSys antibody developed both for therapy and for research and diagnostics. Sales in fiscal 2012 amounted to 51.9 million euros, net profit was 1.9 million euros.
- 2.1 Board of Directors
- 2.2 Shareholder
Business
Most important technology of MorphoSys is an antibody library HuCAL ® name, which is used by researchers for the production of human antibodies. This collection includes more than ten billion different human antibodies in the form of a phage display library. The MorphoSys AG provides several partner companies in return for royalties, the HuCAL ® library, either for the development of therapeutic agents based on monoclonal antibodies or for research purposes.
The MorphoSys AG receives in the drug development partnerships also serving milestone payments upon the achievement of certain development goals ( for example, delivery of an antibody against a given target molecule, the beginning of the clinical trial with a HuCAL ® antibodies, licensed as a drug ). This milestone payments add up each drug project total of around $ 10 million. The more advanced a project in development is, the higher the individual payments usually fall out. At the sales of finished drugs developed from the projects which MorphoSys AG is also involved.
The partner company of MorphoSys AG now include 11 of the top 20 international pharmaceutical companies:
- Bayer Schering Pharma
- Boehringer Ingelheim
- Novartis AG
- Johnson & Johnson
- Merck & Co.
- Pfizer
- Eli Lilly and Company
- Roche
- Schering -Plough
- Daiichi Sankyo
In January 2005, the British -based Biogenesis Group MorphoSys AG took over for 5:25 million pounds (about 6.3 million EUR ). In January 2006, MorphoSys acquired the British Serotec Group for £ 20 million ( approximately EUR 24 million ). With the merger of the two brands to AbD Serotec MorphoSys AG so that the rose by its own account on the largest supplier of antibodies for research in Europe. In December 2012, the California biotechnology company Bio -Rad Laboratories took over the research and diagnostics segment AbD Serotec against payment of EUR 48 million plus a royalty payment for the use of the HuCAL ® technology. In October 2010, MorphoSys AG took over the resident Puchheim private Sloning Biotechnology GmbH for EUR 19 million.
The MorphoSys AG has been profitable since late 2004, which is not self-evident in the biotech sector. Currently has been developed based on the HuCAL ® technology ready for the market yet, no drug.
Clinical trials
The specially developed antibody MOR103 GM -CSF in rheumatoid arthritis is currently undergoing a clinical trial, phase Ib / IIa. The most advanced affiliate programs come from Centocor and Novartis with CNTO888 with BHQ880 and are currently each in a clinical trial phase II Total current six- house drug and over 65 developed by partner companies based on the HuCAL ® technology are.
Business
The MorphoSys AG was founded in 1992. Among the founders of the company include the initiator Christian Schneider, who conceived the business concept and the technology platform, the current CEO Simon E. Moroney and Plückthun as a scientific advisor.
Board of Directors
- Simon Moroney (Chairman)
- Marlies Sprollenhaus (Research)
- Arndt Schottelius (Development)
- Jens Holstein (finance)
Shareholder
- Novartis Pharma AG 7 %
- AstraZeneca 6%
- Management Board and Supervisory Board 2%
- Free float 85 %, of which Institutional investors 38%
- Private investors 30 %
- Unidentified 17%
As of March 2010